Biopharma Transcript

Accuray Incorporated ARAY

Nasdaq · oncology · device-combination · EDGAR · Updated Nov 7, 2026

Accuray Incorporated (Nasdaq: ARAY) is an oncology medical device company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Pipeline

ProgramIndicationModalityStage
Tomo C radiation therapy systemRadiation oncologydevice-combinationNA_NON_THERAPEUTIC
CyberKnife S7 SystemRadiation oncologydevice-combinationNA_NON_THERAPEUTIC
Radixact SynC SystemRadiation oncologydevice-combinationNA_NON_THERAPEUTIC
Accuray Stellar SystemRadiation oncologydevice-combinationNA_NON_THERAPEUTIC
Accuray Helix SystemRadiation oncologydevice-combinationNA_NON_THERAPEUTIC
Accuray Precision Treatment Planning SystemRadiation therapy planningdevice-combinationNA_NON_THERAPEUTIC

Recent results and decisions

  1. Nov 4, 2026
    positive Long-term PACE-A data presented at ASTRO showed excellent eight-year biochemical control for SBRT with quality-of-life advantages over surgery.Long-term PACE-A data presented at ASTRO showed excellent eight-year biochemical control for SBRT, with about 75% of SBRT patients treated with the CyberKnife System. Filing

For subscribers

Other oncology companies